TNYA

Equibles Rating blended score · not investment advice

Overall

Buy

Technical · trend & momentum Buy

◦ 50 / 200-day cross no cross

− Price vs 200-day avg −12% below

+ Price vs 50-day avg +12% above

◦ RSI (14) 66 · neutral

+ MACD trend positive

◦ 52-week position 18% · mid-range

Sentiment · smart money Bullish

◦ Trend (MA cross) 50d $1 › 200d $1 — 200d above 50d

+ Institutional flow +6% holders QoQ · +26 funds added

− Insider flow Net -$6.3K over 90 days · 100% sells

+ Short interest 13.21% of float · ▼ -2.2% MoM · 8.4 days cover

◦ Volume signal Volume near normal

◦ Institution breadth 103 holders — mid 3-yr range

Fundamentals Strong

+ EPS growth +55% Y/Y

− Free cash flow $-68.9M

+ Balance sheet net cash $100.5M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 8, 2026 Est · unconfirmed · in 5 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 6, 2026

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

−12% below Bearish

Price vs 50-day avg

+12% above Bullish

RSI (14)

66 · neutral Neutral

MACD trend

positive Bullish

52-week position

18% · mid-range Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Accumulating

+6% holders QoQ · +26 funds added

Insider flow Distributing

Net -$6.3K over 90 days · 100% sells

Short interest Falling

13.21% of float · ▼ -2.2% MoM · 8.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

103 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $1 Now $1 · 18% 52-wk high $2

vs 200-day avg -12% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TNYA Tenaya Therapeutics, Inc. this stock	$187.79M	+21.5%	—	—	13.2%
AKTX Akari Therapeutics Plc	$953.21B	-9.9%	—	—	0.0%
ONC BeOne Medicines Ltd.	$470.30B	-2.0%	+22179.2%	957.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.41B	+16.8%	+46.2%	31.4	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.80B	-15.1%	+20.8%	16.3	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

103

% held: 25.2%
Net QoQ: -14.3M sh
Top holder: VANGUARD CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

28.7M

Days to cover: 8.4d
Change: -630.7K sh

View

Short Volume

Short vol %

32%

As of: Jul 6, 2026

Short Total

View

Fails to Deliver

FTD shares

643

Value: $450
As of: Jun 11, 2026

View

Off-Exchange

Off-exchange %

73.7%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$6.3K

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Financials

Net income (FY)

$-90.6M

EPS diluted: $-0.59

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 2, 2026
This year: 11

View

Proposed Sales

Value

$596.6K

Shares: 1.1M
Filed: Feb 25, 2026

View

Earnings & Events

Earnings Calls

Last call

May 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
TNYA	+20.5%	+12.1%	+13.1%	+17.1%	+21.5%
SPY	+3.1%	-0.8%	+8.2%	+0.6%	+10.2%
vs SPY	+17.4%	+12.8%	+4.8%	+16.5%	+11.3%

Price & Indicators

Technicals

Versus peers

At a glance

Performance